Vaccine and drugs before reduced radiation for HPV throat cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new combination of drugs and a vaccine before standard radiation for HPV-positive throat cancer. It aims to use a less intense radiation dose, which may reduce side effects while still being effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your throat cancer must be HPV-positive (a virus-related type).
- The cancer must be locally advanced, meaning it is large or has spread to lymph nodes in the neck, but not to distant organs.
- You must not have had prior chemotherapy, radiation, or surgery for this cancer (a biopsy is okay).
- You need to be in generally good health, with adequate blood counts and organ function, and no serious heart or immune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This trial tests whether using a lower intensity (reduced) chemo-radiation plan can work for some people with HPV-related oropharyngeal (throat) cancer without losing effectiveness. It may help reduce side effects while still controlling the cancer.
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
This trial tests a lower dose of radiation to certain neck areas for people with HPV-related oropharyngeal cancer. The goal is to see if reducing radiation can cause fewer side effects while still curing the cancer.
This trial studies whether adding a precise “extra boost” to radiation can work as well as (or better than) standard radiation for HPV-related oropharynx cancer, while keeping the overall treatment shorter. It may help improve tumor control while aiming for manageable side effects.
This study tests a new drug (ATRN-119) combined with focused radiation before surgery for people with early-stage HPV-positive throat cancer. It aims to see if this combination can shrink tumors and improve outcomes.
Hear when a new HPV Positive Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.